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Abstract
Corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and a subset of 
frontotemporal dementia (FTD) are neurodegenerative disorders characterized by tau inclusions in 
neurons and glia (tauopathies). Although clinical, pathological and genetic evidence suggests 
overlapping pathobiology between CBD, PSP, and FTD, the relationship between these disorders 
is still not well understood. Using summary statistics (odds ratios and p-values) from large 
genome-wide association studies (total n = 14,286 cases and controls) and recently established 
genetic methods, we investigated the genetic overlap between CBD and PSP and CBD and FTD. 
We found up to 800-fold enrichment of genetic risk in CBD across different levels of significance 
for PSP or FTD. In addition to NSF (tagging the MAPT H1 haplotype), we observed that SNPs in 
or near MOBP, CXCR4, EGFR, and GLDC showed significant genetic overlap between CBD and 
PSP, whereas only SNPs tagging the MAPT haplotype overlapped between CBD and FTD. The 
risk alleles of the shared SNPs were associated with expression changes in cis-genes. Evaluating 
transcriptome levels across adult human brains, we found a unique neuroanatomic gene expression 
signature for each of the five overlapping gene loci (omnibus ANOVA p < 2.0 × 10−16). 
Functionally, we found that these shared risk genes were associated with protein interaction and 
gene co-expression networks and showed enrichment for several neurodevelopmental pathways. 
Our findings suggest: i) novel genetic overlap between CBD and PSP beyond the MAPT locus; ii) 
strong ties between CBD and FTD through the MAPT clade, and; iii) unique combinations of 
overlapping genes that may, in part, influence selective regional or neuronal vulnerability observed 
in specific tauopathies.
INTRODUCTION
Collectively referred to as tauopathies, corticobasal degeneration (CBD), progressive 
supranuclear palsy (PSP) and a subset of frontotemporal dementia (FTD) spectrum disorders 
are neurodegenerative diseases defined by the intracellular, abnormal filamentous 
accumulations of the microtubule associated protein tau, encoded by MAPT [26]. 
Neuropathologically, tau deposits in CBD and PSP consist primarily of 4-repeat (4R) tau 
inclusions, and a large fraction of insoluble tau is present within neurons, astrocytes and 
oligodendrocytes [25]. Whereas CBD pathology predominantly affects forebrain structures 
(including the neocortex) and midbrain structures (including the substantia nigra), PSP 
pathology demonstrates a predilection for affecting hindbrain regions including the tectum, 
tegmentum, midbrain as well as the globus pallidus and diecephalon [14, 16]. In 
comparison, approximately half of FTD spectrum cases, encompassing behavioral variant 
FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), non-fluent variant 
PPA (nfvPPA), and FTD overlapping with motor neuron disease (FTD-MND), are caused by 
underlying tau pathology. Approximately half of bvFTD clinical syndromes result from 
underlying Pick’s disease, which is characterized by predominantly 3R tau inclusions (Pick 
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bodies) in the frontal, temporal and insular cortical gray matter [25]. The majority of nfvPPA 
clinical cases are due to underlying tau pathology, including PSP, CBD, and Pick’s disease 
[9, 17, 21, 28]. Although neuropathologically distinct, there is considerable molecular and 
biomarker overlap between CBD, PSP and a subset of FTD [13]. Importantly, the biological 
basis of selective neuroanatomic or neuronal vulnerability within each tauopathy is poorly 
understood.
Genetic factors can offer novel insight into molecular mechanisms underlying disease risk. 
Recent genome-wide association studies (GWAS) have shown that single nucleotide 
polymorphisms (SNPs) within the H1 haplotype of the MAPT locus are associated with 
increased risk for CBD, PSP, and FTD [20, 24, 32]. Additionally, GWAS of pathologically 
confirmed CBD cases and from clinically and pathologically defined PSP cases have 
independently identified SNPs within MOBP as increasing disease risk [24] indicating that 
shared genetic risk may explain susceptibility to tau aggregates. Still, few, if any, studies 
have systematically evaluated genetic overlap between these three tauopathies.
Combining GWAS from multiple disorders and phenotypes provides insights into genetic 
pleiotropy (defined as a single gene or variant being associated with more than one distinct 
phenotype) and could identify shared genetic risk factors. In this study, using recently 
validated methods for systematically assessing genetic overlap, we investigated shared gene 
loci between tauopathies. Taking advantage of several large GWAS [15, 20, 24], we sought 
to identify SNPs jointly associated with CBD and PSP or FTD.
METHODS
Participant samples
We evaluated complete GWAS results in the form of summary statistics (p-values and odds 
ratios) for CBD, FTD and PSP (see Table 1). We assessed GWAS summary statistic data 
from 152 autopsy-proven CBD cases and 3,311 controls at 533,898 SNPs (Table 1). The 
CBD GWAS sample has been previously described in detail (see [24]). Briefly, the CBD 
cases were collected from eight institutions and controls were recruited from the Children’s 
Hospital of Philadelphia Health Care Network. The National Institute of Health Office of 
Rare Diseases Research criteria were used for making a neuropathologic diagnosis of CBD 
[12]. We obtained phase I FTD-GWAS summary statistic data from the International FTD-
Genomics Consortium (IFGC), which consisted of 2,154 clinical FTD cases and 4,308 
controls with genotyped and imputed data at 6,026,384 SNPs (Table 1, for additional details, 
see [15]). The FTD dataset included multiple subtypes within the FTD spectrum: bvFTD, 
semantic dementia, progressive non-fluent aphasia, and FTD overlapping with motor neuron 
disease. We obtained publicly available PSP-GWAS summary statistic data from the NIA 
Genetics of Alzheimer’s Disease Storage Site (NIAGADS), which consisted of 1,114 
individuals with PSP (cases) and 3,247 controls (stage 1) at 531,451 SNPs (Table 1, for 
additional details see [20]). The relevant institutional review boards or ethics committees 
approved the research protocol of the individual GWAS used in the current analysis, and all 
human participants gave written informed consent.
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Identification of shared risk loci -- conjunction FDR
Using recently developed statistical methods to evaluate shared genetic risk [1–3, 10, 11], 
we evaluated SNPs associating with CBD and FTD and CBD and PSP. For given associated 
phenotypes A and B, genetic ‘enrichment’ of phenotype A with phenotype B exists if the 
proportion of SNPs or genes associated with phenotype A increases as a function of 
increased association with phenotype B. To assess enrichment, we constructed fold-
enrichment and conditional Q-Q plots of nominal −log10(p) values for all CBD SNPs and for 
subsets of SNPs determined by the significance of their association with PSP and with FTD 
(for additional details see Supplemental Information). Enrichment seen can be directly 
interpreted in terms of true discovery rate (TDR = 1 – False Discovery Rate (FDR)) (for 
additional details see Supplemental Information and [1, 3, 10, 11]). Since ‘genetic 
enrichment’ is dependent on GWAS sample size [1], we applied our analysis focused on the 
CBD sample, the smallest available GWAS cohort.
To identify specific loci involved in both CBD and PSP or CBD and FTD, we computed 
conjunction FDR [1, 3, 36]. Conjunction FDR, denoted by FDRtrait1& trait2 is defined as the 
posterior probability that a SNP is null for either phenotype or for both simultaneously, 
given the p-values for both traits are as small, or smaller, than the p-values for each trait 
individually (see [36] and Supplemental Information for more details). We used an overall 
FDR threshold of < 0.05. Additionally, we constructed Manhattan plots based on the ranking 
of conjunction FDR to illustrate the genomic location of the shared genetic risk loci.
Functional evaluation of shared risk loci
To assess whether the CBD, PSP, and FTD overlapping SNPs modify expression of genes, 
we evaluated cis-expression quantitative trait loci (eQTLs) in a publicly available dataset 
from neuropathologically confirmed normal control brains (UKBEC, http://braineac.org/) 
[29]. To minimize multiple comparisons, we focused on the average p-value derived from 
individual p-values from the cerebellum, frontal cortex, hippocampus, medulla, occipital 
cortex, putamen, substantia nigra, temporal cortex, thalamus, and white matter. To minimize 
risk of false positives, we used a Bonferroni corrected p-value (0.05/number of shared loci). 
We further assessed cis-eQTLs using a neurodegenerative dataset containing genotypic and 
gene expression data from Alzheimer’s Disease [AD] (cerebellar expression GWAS 
(eGWAS) n = 197, temporal cortex eGWAS = 202) and PSP brains (cerebellar eGWAS = 98, 
temporal cortex eGWAS = 107) (for additional details see [38]). Finally, we also evaluated 
eQTLs using a blood-based dataset [33]. We used an analysis of covariance (ANCOVA) to 
test for association between genotypes and gene expression. We tested SNPs using an 
additive model.
Delineating differential regional expression of shared genetic risk variants
To evaluate whether the genes associated with the identified CBD, PSP, and FTD risk SNPs 
demonstrate a regionally specific pattern of expression across the human brain, we used the 
publicly available 6 human brain transcriptome data set from the Allen Brain Science 
Institute (for additional details see http://human.brain-map.org/ and [19]). Briefly, 
approximately 500 anatomically discrete samples were collected from cortex, subcortex, 
cerebellum, and brainstem of each brain and profiled for genome-wide gene expression 
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using a custom Agilent 8x60K cDNA array chip. For additional details regarding the 
dissection methods, quality control, and normalization measures on this dataset, please see 
[19] and http://human.brain-map.org/. For each gene associated with the shared SNPs, we 
downloaded expression values, calculated using z-score normalization. Using a repeated 
measures analysis of variance (ANOVA) (across the individual probes) as an omnibus test, 
we first investigated whether there was an overall effect of gene expression across all 
individual brain regions. Next, we calculated the mean of the expression values across each 
probe and across the six subjects and visualized these results using bar plots. Finally, for 
visualization, we mapped the mean expression values (across each probe and six subjects) 
onto the gray matter cortical surface using the Freesurfer image analysis package 
(www.freesurfer.net).
Gene ontology and network based functional association analyses
To identify significant enrichments in gene ontology associated with the PSP, CBD, and 
FTD pleiotropic genes, we used the ToppGene portal (https://toppgene.cchmc.org/). To 
evaluate potential protein and genetic interactions, co-expression, co-localization and protein 
domain similarity between the overlapping genes, we used GeneMANIA 
(www.genemania.org), an online web-portal for bioinformatic assessment of gene networks.
RESULTS
Shared genetic risk between tauopathies
We observed considerable SNP enrichment for CBD across different levels of significance 
with PSP and FTD (Figure 1). Using progressively stringent p-value thresholds for CBD 
SNPs (i.e. increasing values of nominal −log10(p)), we found up to 800-fold genetic 
enrichment using PSP and 400-fold genetic enrichment using FTD (Figure 1). Conditional 
Q-Q plots similarly demonstrated polygenic enrichment in CBD as a function of PSP and 
FTD (Supplemental Figure 1).
At a conjunction FDR < 0.05, we identified 5 SNPs that were associated with increased risk 
for CBD and PSP (Figure 2, Table 2, Supplemental Figures 2a–2e). These included: 1) 
rs199533 (exonic; NSF, CBD and PSP (and FTD), FDR p = 3.85 × 10−5); 2) rs1768208 
(intronic; MOBP, CBD and PSP, FDR p = 2.68 × 10−3); 3) rs2011946 (intergenic; closest 
gene = CXCR4, CBD and PSP, FDR p = 0.038); 4) rs759162 (intronic; EGFR, CBD and 
PSP, FDR p = 0.045); and 5) rs7035933 (intronic; GLDC, CBD and PSP, FDR p = 0.045). 
We note that rs199533 is in strong linkage disequilibrium (LD) with SNP rs1800547, which 
tags the H1 haplotype of MAPT (pairwise D′ = 1, r2 = 0.94).
Although we excluded any GRN mutation carriers, given prior work illustrating TDP-43 
pathology predominantly within svFTD, nfv-FTD and FTD-MND, one concern is that 
TDP-43, rather than tau pathology, may be influencing our results. To test this possibility, 
we performed sub-group analyses by excluding svFTD, nfv-FTD and FTD-MND 
individuals and specifically evaluated genetic overlap between CBD and bvFTD (FTD 
subtype which is enriched for tau pathology) and CBD and PSP. As illustrated in 
Supplemental Figures 3a–3b, limiting our analyses to the bvFTD subtype, we found similar 
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results as using the combined sporadic FTD cohort suggesting that our CBD-FTD findings 
may be strongly influenced by tau, rather than TDP-43, pathology.
We further assessed whether the observed genetic overlap between CBD, PSP and FTD was 
polygenic and generalizable across a number of loci or non-polygenic and driven by the 
MAPT region alone. Removing the chromosome 17 MAPT-region associated signal, 
consisting of all SNPs in r2 > 0.2 (based on 1000 Genomes Project LD structure) within 1 
Mb of MAPT variants, we found considerable diminishment in genetic enrichment in CBD 
as a function of FTD (Supplemental Figures 4a–4b) further indicating that the observed 
overlap between CBD and FTD is non-polygenic and likely confined to the MAPT region. 
In contrast, evaluating genetic enrichment in CBD as a function of PSP after removing the 
MAPT region, we still found up to 80-fold enrichment suggesting that although the MAPT 
locus accounts for a large component of observed genetic overlap, variants beyond the 
MAPT region still contribute to shared genetic risk between CBD and PSP (Supplemental 
Figures 4a–4b).
eQTL analyses
Evaluating cis-eQTLs, at a previously established conservative Bonferroni corrected p-value 
< 3.9 × 10−5 [23], we found that rs199533 was significantly associated with MAPT (p=2 × 
10−12) and a number of other transcripts in the MAPT region including KIAA1267 (p = 2.4 
× 10−24), LOC1 (p = 1.1 × 10−23), C17orf58 (p=2.1 × 10-6) and LOC100294337 (p=2.2 × 
10−6). As illustrated in Supplemental Figure 2a, rs199533 is in high LD with numerous 
SNPs within the MAPT haplotype block (including MAPT) that have a robust association 
with increased risk for tauopathy. Although rs199533 is linked to SNPs tagging the MAPT 
inversion region that distinguishes the H1 or H2 haplotype, reports vary as to the effects of 
MAPT haplotypes on gene expression (for a review of this topic see [23]). Whereas previous 
studies suggested that MAPT H1 is associated with increased production of pre-mRNA 
transcripts with exon 10 (making more 4R tau protein), more recent findings have indicated 
that the association with exon 10 maybe driven by a technical artifact [31]. Instead, it has 
been suggested that the MAPT H1 haplotype is associated with decreased expression of pre-
mRNA transcripts containing exons 2/3 (2N tau protein). Using the UKBEC dataset, we 
assessed the effects of rs199533 on MAPT splicing by testing eQTLs in probes that 
specifically tag regions of the MAPT transcript, namely exon 3, exon 2, and exon 10. 
Applying a conservative Bonferroni corrected p-value < 3.9 × 10−5 [23] across the four 
probes, we found a specific and significant eQTL between rs199533 and exon 3 (average p-
value across ten regions = 2 × 10−12). In comparison, rs199533 and exon 2 (p-value = 0.02) 
and exon 10 (p-value = 0.04) demonstrated weaker eQTLs. Conditional analysis from the 
original PSP GWAS [20] found that rs242557 (in the promoter region of MAPT) was 
associated with increased disease risk, even after controlling for the H1/H2 clade, suggesting 
a MAPT sub-haplotype. We note that neither rs242557 nor a highly linked SNP, rs242562, 
are available in the UKBEC dataset (which we used to perform the exon-specific splicing 
analysis) and as such, we cannot exclude the possibility that a MAPT sub-haplotype is 
associated with increased inclusion of exon 10. Taken together, our results strongly suggest 
that variants within MAPT underlie the shared genetic risk observed on chromosome 17 and 
these variants alter expression of specific MAPT isoforms.
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We also sought to investigate the functional impact of the other top SNPs for their role in 
gene expression of the loci they represent. As illustrated in Table 3, using the GTEX dataset, 
we found numerous significant eQTLs between rs2011946 and MCM6 (within the CXCR4 
region, see Supplemental Figure 2c), rs1768208 and MOBP and rs7035933 and GLDC. 
Using the UKBEC dataset, we additionally evaluated the relationship between rs1768208 
and SLC5A38 expression (see Supplemental Figure 2b) and found a non-significant eQTL 
with the total probe (p-value = 0.56) further suggesting that our GWAS signal is localizing to 
the MOBP locus on chromosome 3. We also found that rs2011946 is associated with 
CXCR4 expression in whole blood (p-value = 1.82 × 10−6) [33]. This eQTL is consistent 
with the function of CXCR4 in macrophages and microglia [27]. Although we cannot 
exclude other genes, our whole blood and GTEX eQTLs suggest that variants within the 
CXCR4 region likely underlie our pleiotropic signal observed on chromosome 2. To further 
evaluate co-localization of eQTL and GWAS signals, we used COLOC (https://github.com/
chr1swallace/coloc). Compatible with our eQTL results using the UKBEC and GTEX 
cohorts, our co-localization results confirm that the eQTL and GWAS signals are likely 
driven by the same causal SNPs (Supplemental Table 2).
Finally, we examined cis-eQTLs for rs199533 in a dataset containing genetic and expression 
data from control, AD and PSP human brain tissue [38]. We found numerous significant 
eQTLs in the cerebellum and frontal cortex (Supplemental Table 1). Both regions showed 
robust MAPT eQTLs, along with other loci (e.g., LRRC37A). We also found a significant 
eQTL between rs1768208 and MOBP within the temporal cortex (ILMN_1768947; p-value 
= 3.03×10−3).
Delineating differential regional expression of shared variants
For each of the 5 shared risk genes, across the 26 brain regions, we found a significant 
overall effect for differential expression of MAPT (omnibus repeated measures ANOVA F 
(4,25) = 16.8, p-value = < 2.0 × 10−16); MOBP (F (2,25) = 16.19, p-value = < 2.0 × 10−16); 
CXCR4 (F (2,25) = 16.19, p-value = < 2.0 × 10−16); EGFR (F (4,25) = 14.6, p-value = < 2.0 
× 10−16); and GLDC (F (4,25) = 14.6, p-value = < 2.0 × 10−16) indicating differential 
expression across brain regions. As illustrated in Figures 3 and 4, we found that each 
transcript showed a unique regional expression profile, all of which correspond to the 
neuroanatomical regions most affected in CBD, PSP, and FTD (Figure 5). Localized 
predominantly to the cerebral cortex, MAPT demonstrated the highest levels of expression 
within the temporal lobe, parietal lobe, parahippocampal gyrus, insula, and cingulate gyrus 
(Figures 3 and 4). Using the neocortical focused Braineac dataset, we independently 
confirmed this cortical pattern for MAPT regional expression (Supplemental Figure 5). 
MOBP showed the highest expression within the white matter and ventral thalamus (Figure 
4). CXCR4 demonstrated the highest expression within subcortical and deep gray structures 
(ventral thalamus, subthalamus, pontine tegmentum, and cerebellar nuclei) (Figure 4). EGFR 
showed the highest expression within the basal ganglia (globus pallidus, striatum), midbrain 
(mesencephalon and thalamus), and brainstem (myelencephalon and pontine tegmentum) 
(Figure 4). GLDC showed highest expression within the amygdala, cingulate gyrus, 
temporal lobe and claustrum (Figure 4). Interestingly, none of the 5 genes demonstrated 
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elevated expression within the hippocampal formation, a region preferentially affected in 
AD.
Gene ontology and gene-protein network analyses
At FDR < 0.05, we found that MAPT, MOBP, CXCR4, GLDC, and EGFR were enriched for 
multiple gene ontology (GO) molecular, cellular, and biological pathways (Table 4). 
Interestingly, we found that these shared loci were enriched for several neurodevelopmental 
processe including telencephalic cell migration, forebrain cell migration, neuron projection 
morphogenesis, and neuron migration (q-value FDR < 0.05, Table 4). We found physical 
interaction and gene co-expression networks between MAPT, MOBP, CXCR4, GLDC, and 
EGFR (Figure 6). As illustrated in Supplemental Table 3, we found several ‘network’ based 
effects including physical interactions between CXCR4 and CXCL12 and TLR2, GLDC and 
AMT, and shared protein domains between MAPT and MAP4.
DISCUSSION
In this study, we identified genetic overlap between CBD, PSP, and FTD illustrating shared 
pathobiology between these diseases characterized primarily (PSP and CBD) or in part 
(FTD) by tau aggregation. Although MAPT and MOBP represented the strongest findings, 
we detected novel shared risk signals within CXCR4, EGFR and GLDC. Evaluating RNA 
levels across various brain regions, we detected a unique neuroanatomic gene expression 
signature for each of the five candidate genes. Functionally, we found that the genes 
representing these shared risk loci were associated with protein interaction and gene co-
expression networks and showed enrichment for several neurodevelopmental pathways. 
Considered together, our results illustrate genetic overlap between tauopathies at and beyond 
the MAPT clade. These findings also suggest that a specific genetic combination of shared 
risk variants may determine selective vulnerability and thus influence whether a tauopathy-
susceptible individual develops neurodegeneration within a frontotemporal (FTD), peri-
rolandic (CBD), or midbrain/hindbrain (PSP) pattern.
By combining GWAS from multiple neurodegenerative diseases, our results suggest shared 
molecular pathways between these three tauopathies. Consistent with prior clinical and 
neuropathological observations that CBD and PSP exist along a 4R tauopathy spectrum [13], 
we found up to 800-fold genetic enrichment in CBD as a function of PSP illustrating 
considerable shared pathobiology that involves MAPT and non-MAPT regions. We also 
detected up to 400-fold genetic enrichment in CBD and FTD indicating overlap between 3R 
and 4R diseases, localized predominantly to the MAPT region. It should be noted that the 
GWAS for CBD and PSP utilized the same control series for analysis. Since we utilized 
summary statistics for the analysis, we cannot exclude the possibility that some of the shared 
genetic risk between these two disorders is driven by the controls.
By leveraging variants associated with increased risk for both PSP and FTD, we were able to 
identify variants associated with increased risk for CBD that have not been detected using a 
single phenotype approach. Beyond the known overlap between CBD and PSP at MAPT and 
MOBP [20, 24], we found novel genetic overlap within loci representing CXCR4, EGFR 
and GLDC. MOBP encodes myelin-associated oligodendrocyte basic protein, a Rab GTPase 
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critical for myelin sheath stabilization. Chemokine receptor CXCR4 encodes a protein 
important in vascularization and cerebellar development. EGFR encodes epidermal growth 
factor receptor. GLDC encodes glycine dehydrogenase, a critical enzyme required for 
glycine degradation; mutations in GLDC cause glycine encephalopathy due to abnormally 
high levels of glycine in brain. Importantly, we found that the majority of these shared risk 
loci were either expressed in the brain (rs199533/MAPT, rs1768208/MOBP) or within 
macrophages/microglia (rs2011946/CXCR4). The biological roles of these different 
candidates coupled with their differential expression patterns in the brain support the idea 
that these genetic risk factors may promote specific neuroanatomical patterns of tauopathy 
when observed in different combinations. Considered together with prior work, our genetic 
findings together indicate that neuropathobiological alterations beyond the tau region are 
likely involved across tauopathies.
Evaluating RNA transcripts from six adult human brains, we identified a unique 
neuroanatomic gene expression signature for each of the five candidate genes. Building on 
prior studies evaluating MAPT expression within the normal adult brain [31], we found 
elevated total MAPT expression selectively within the neocortex. Across all evaluated 
regions, total MAPT RNA levels were highest within the temporal lobe, one of the earliest 
regions implicated in FTD ([4], see Figure 5). Interestingly, we did not find elevated total 
MAPT expression within the hippocampus, a brain region susceptible to tau pathology in 
middle and old age [7]. In contrast to MAPT and compatible with its known function in 
normal myelin formation [35], MOBP showed highest expression within white matter 
indicating that genetic variants associated with MOBP may play a role in selectively 
affecting white matter regions known to be involved with frontotemporal lobar degeneration 
[8], most strikingly in CBD. Interestingly, CXCR4 and EGFR demonstrated elevated 
transcripts within the cerebellum and deep gray nuclei (thalamus and globus pallidus), 
regions more affected in CBD and PSP than FTD [6, 22, 34]. Considered together with our 
shared genetic risk findings, these gene expression results suggest that unique combinations 
of risk variants may influence selective regional vulnerability within the specific tauopathies.
Functionally, we found several gene-gene and gene-protein network-based associations 
between MAPT, MOBP, CXCR4, GLDC, and EGFR. Compatible with prior work showing 
the integral biophysical and molecular relationships between the chemokine CXCL12 
(SDF-1) and its receptor CXCR4 [30], we detected a strong physical interaction between 
CXCR4 and CXCL12 in our bioinformatic analysis. Interestingly, although the CXCL12/
CXCR4 axis has been described as a regulator of leukocyte trafficking and immune 
responses, recent evidence suggests that these chemokines are pleiotropic and may also be 
necessary for normal cell migration within the cerebral cortex [5] and cerebellum [18]. 
Building on these findings, we additionally found that our CBD, PSP, and FTD shared risk 
genes were enriched for several neurodevelopmental processes including neuron migration, 
tubulin complex, and neuron projection morphogenesis. Considered together, these results 
provide compelling support for shared genetic risk for tauopathies and suggest that genes 
critical for normal brain development may also influence brain degeneration.
The regional expression differences we observed occur in the context of a dataset derived 
from brain homogenates, which are composed of many different types of cells. While we are 
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unable to disentangle the exact contribution of each cell type to the observed regional 
expression differences, a separate dataset of transcriptomic information derived from single 
cell types from brain [37] provides indirect evidence that specific subtypes of cells may be 
driving these patterns in a gene-dependent manner (Fig S6). For example, MAPT expression 
is observed to be highest in neurons when compared to other cell types in the brain. In 
contrast, MOBP is far more highly expressed in oligodendrocytes versus any other cell type, 
consistent with its role in myelination. CXCR4 is expressed most highly in microglia/
macrophages as would be expected for a gene implicated in immune function. EGFR and 
GLDC both show highest expression in mature astrocytes, though the differences in 
expression in this cell type are not as marked as for some of the other, more specialized 
protein-encoding transcripts (i.e., MOBP, CXCR4). Together, the differential expression 
patterns of each gene candidate are consistent with their function and support a mechanism 
by which gene expression at both a regional and cell-specific level may contribute to 
selective vulnerability to particular cell types to tau pathology.
Our results indicate that common genetic variability at the MAPT haplotype and the MOBP, 
CXCR4, EGFR and GLDC genes may influence the regional pattern of volume loss—and 
thus disease phenotype—in individuals at risk for developing a specific tauopathy. For 
example, patients with MAPT and CXCR4 susceptibility variants may be at greater risk for 
developing PSP than either FTD or CBD. Similarly, patients with MAPT, MOBP and GLDC 
may have a higher risk for developing CBD or FTD than PSP. Furthermore, the 
identification of a SNP that modifies a gene highly expressed in microglia (CXCR4) 
highlights the critical role of microglia in tau-mediated neurodegeneration.
In summary, beyond the extended MAPT haplotype, we found novel genetic overlap 
between CBD and PSP. Conversely, the extended MAPT haplotype represented the only 
pleiotropic locus for CBD and FTD. Each of these tauopathy-associated pleiotropic variants 
was associated with a unique neuroanatomic gene expression signature that may influence 
regional and neuronal selective vulnerability. Although no single common variant maybe 
informative clinically, the combination of these risk variants may in part drive whether a 
tauopathy-susceptible older individual develops CBD, PSP, or FTD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Fold enrichment plots of enrichment versus nominal −log10 p-values (corrected for inflation) 
in corticobasal degeneration (CBD) below the standard GWAS threshold of p < 5×10−8 as a 
function of significance of association with progressive supranuclear palsy (PSP, left panel) 
and frontotemporal dementia (FTD, right panel) and at the level of −log10(p) ≥ 0, −log10(p) 
≥ 1, −log10(p) ≥ 2 corresponding to p ≤ 1, p ≤ 0.1, p ≤ 0.01, respectively. Blue line indicates 
all SNPs.
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Figure 2. 
‘Conjunction’ Manhattan plot of conjunction and conditional −log10 (FDR) values for 
corticobasal degeneration (CBD) (black) given progressive supranuclear palsy (PSP; CBD|
PSP, red) and frontotemporal dementia (CBD; CBD|FTD, orange). SNPs with conditional 
and conjunction −log10 FDR > 1.3 (i.e. FDR < 0.05) are shown with large points. A black 
line around the large points indicates the most significant SNP in each LD block and this 
SNP was annotated with the closest gene, which is listed above the symbols in each locus.
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Figure 3. 
Average regional gene expression of MAPT and MOBP from 6 postmortem subjects from 
the Allen Brain Science Institute mapped into a three dimensional reconstruction (‘inflated’ 
view) of the gray/white matter boundary of the cerebral cortex (fsaverage subject from 
FreeSurfer). Top panels illustrate the lateral view and bottom panels illustrate the medial 
view of the left cerebral hemisphere.
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Figure 4. 
Color-coded bar plots illustrating mean regional transcript levels for MAPT, MOBP, 
CXCR4, EGFR and GLDC using data from the Allen Brain Science Institute. Values 
represent z-scores averaged across the individual probes and across the 6 postmortem 
subjects.
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Figure 5. 
Voxel based morphometry results illustrating atrophy patterns for FTD (red), CBD (blue), 
PSP (yellow), and overlap of all three tauopathies. Results are shown as T-map overlays 
(p<0.001) of volume loss in patients versus controls, and heat map reflects overlap between 
tauopathies. Atrophy patterns were derived from a cohort of individuals clinically diagnosed 
and pathologically confirmed to have CBD (n=6), FTD Pick’s disease (n=5), or PSP (n=17), 
which was compared to a cohort of cognitively normal healthy older controls (n=180, mean
±SD 66.1±8.5 years). For detailed methods and results, see Supplemental Material.
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Figure 6. 
Network interaction graph illustrating physical interactions (pink), co-expression (purple), 
predicted (orange), pathway (aqua), co-localization (blue), gene interactions (green) and 
shared protein domains (khaki) for CXCR4, MOBP, EGFR, GLDC, and MAPT.
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Table 1
Summary data from all GWAS used in the current study
Disease/Trait Total N # SNPs Reference
Corticobasal degeneration (CBD) – phase 1 3,463 533,898
Kouri N, et al. Genome-wide association study of corticobasal 
degeneration identifies risk variants shared with progressive 
supranuclear palsy. Nat Comm. 2015;6:7247.
ProgressiveSupranuclear Palsy (PSP) – 
phase 1 4,361 531,451
Höglinger GU, et al. Identification of common variants influencing risk 
of the tauopathy progressive supranuclear palsy. Nat Genet. 
2011:43:699–705.
Frontotemporal Dementia (FTD) – IFGC 
phase 1 6,462 6,026,384
Ferrari, R et al. Frontotemporal dementia and its subtypes: a genome-
wide association study. Lancet Neuro. 2014:13;686–99.
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Table 4
Top functional associations of the shared risk genes. All associations are at q-value, FDR < 0.05.
GO: Biological pathway GO: Cellular component GO: Molecular function
Telencephalon Cell Migration (EGFR, CXCR4) Multivesicular Body, Internal Vesicle 
Lumen (EGFR)
Glycine Dehydrogenase (Decarboxylating) 
Activity (GLDC)
Forebrain Cell Migration (EGFR, CXCR4) Glycine Cleavage Complex (GLDC) Oxidoreductase Activity (GLDC)
Neuron Projection Morphogenesis (EGFR, 
CXCR4, MAPT)
Shc-Egfr Complex (EGFR) Enzyme Binding (EGFR, CXCR4, MAPT, 
GLDC)
Prolactin Secretion Regulation (EGFR) Multivesicular Body, Internal Vesicle 
(EGFR)
Protein Phosphatase Binding (EGFR, MAPT)
Phospholipasea2 Activation (EGFR) Growth Cone (EGFR, MAPT) Epidermal Growth Factor-Activated Receptor 
Activity (EGFR)
Brain Development (EGFR, CXCR4, MAPT) Site Of Polarized Growth (EGFR, 
MAPT)
Phosphatase Binding (EGFR, MAPT)
Neuron Migration (CXCR4, MAPT) Tubulin Complex (MAPT) Cytoskeletal Protein Binding (EGFR, CXCR4, 
MAPT)
Head Development (EGFR, CXCR4, MAPT) Neurofibrillary Tangle (MAPT) Epidermal Growth Factor Binding (EGFR)
Calcium-Mediated Signaling (EGFR, CXCR4) Late Endosome (EGFR, CXCR4) Structural Constituent Of Myelin Sheath 
(MOBP)
Glycine Catabolic Process (GLDC) Early Endosome (EGFR, CXCR4) Myosin Light Chain Binding (CXCR4)
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